Publications by authors named "Flóra Farkas"

4 Publications

  • Page 1 of 1

Comparison of Composite Measure Remission Targets in Psoriatic Arthritis.

J Rheumatol 2021 Mar 15. Epub 2021 Mar 15.

St. Vincent's University Hospital, Dublin, Ireland; Conway Institute for Biomolecular Research, University College Dublin School of Medicine, Dublin, Ireland; Currently at Borsod-Abaúj-Zemplén County Center Hospital and University Teaching Hospital, Department of Rheumatology, Miskolc, Hungary; Nihon University School of Medicine, Division of Hematology and Rheumatology, Tokyo, Japan; Worcestershire Acute Hospitals NHS Trust, Worcester, UK; Uppsala University Hospital, Uppsala, Sweden. The original cohort was supported by an unrestricted grant from AbbVie. The MOPSA tool was developed with the assistance of an unrestricted grant from Janssen. Address correspondence to: Prof. Oliver FitzGerald, Conway Institute for Biomolecular Research, University College Dublin, Belfield, Dublin 4, Ireland. Email:

Objective: To identify 1) which composite measure is the most stringent target of remission; and 2) which disease component target proves the most difficult to achieve in the different states of MDA, CPDAI, DAPSA and cDAPSA in patients with PsA.

Methods: 258 PsA patients were recruited. Disease remission was evaluated comparing 4 different composite measures and using remission cut-offs as previously proposed (VLDA (MDA 7/7), CPDAI ≤2, DAPSA ≤4, cDAPSA ≤4).

Results: Patients met VLDA criteria in 9.0% of visits, DAPSA remission in 19.8%, cDAPSA remission in 23.4% and CPDAI remission in 30.2%. Of 258 patients, MDA criteria (≥5/7) were fulfilled in 46.5%. Of those in MDA, VLDA criteria were reached in 25.0%. Patients met the pain VAS target in 57.5 % of visits when they were in MDA, 43.3% when in LDA (MDA 5-6/7) and 44.8% when in CPDAI remission. Multivariate regression analysis revealed that pain VAS was the least likely target to be achieved. Patients with inflammatory-type back pain had significantly higher pain scores; furthermore, a significant relationship was seen between BASDAI and pain VAS.

Conclusion: Based on our analysis, VLDA proved the most stringent target of disease remission in PsA compared to CPDAI, DAPSA and cDAPSA. The pain VAS target of ≤1.5 cm was the most difficult component to achieve. CPDAI ≤2 was found to be the least stringent remission target; however, measurements of axial involvement, which contributed to the elevated pain VAS score in patients not achieving VLDA, were only included as a domain in CPDAI.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
March 2021

The Analysis of Human Serum N-Glycosylation in Patients with Primary and Metastatic Brain Tumors.

Life (Basel) 2021 Jan 6;11(1). Epub 2021 Jan 6.

Institute of Chemistry, Faculty of Materials Science and Engineering, University of Miskolc, 3515 Miskolc, Hungary.

The identification of patients with different brain tumors is solely built on imaging diagnostics, indicating the need for novel methods to facilitate disease recognition. Glycosylation is a chemical modification of proteins, reportedly altered in several inflammatory and malignant diseases, providing a potential alternative route for disease detection. In this paper, we report the quantitative analysis of serum N-glycosylation of patients diagnosed with primary and metastatic brain tumors. PNGase-F-digested and procainamide-labeled serum glycans were purified by magnetic nanoparticles, followed by quantitative liquid chromatographic analysis. The glycan structures were identified by the combination of single quad mass spectrometric detection and exoglycosidase digestions. Linear discriminant analysis provided a clear separation of different disease groups and healthy controls based on their N-glycome pattern. Altered distribution of biantennary neutral, sialylated but nonfucosylated, and sialylated-fucosylated structures were found to be the most significant changes. Our results demonstrate that serum glycosylation monitoring could improve the detection of malignancy.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
January 2021

Comparative preclinical evaluation of Ga-NODAGA and Ga-HBED-CC conjugated procainamide in melanoma imaging.

J Pharm Biomed Anal 2017 May 1;139:54-64. Epub 2017 Mar 1.

Department of Medical Imaging, Nuclear Medicine, University of Debrecen, Debrecen, Hungary.

Malignant melanoma is the most aggressive form of skin cancer. The early detection of primary melanoma tumors and metastases using non-invasive PET imaging determines the outcome of this disease. Previous studies have shown that benzamide derivatives (e.g. procainamide) conjugated with PET radionuclides specifically bind to melanin pigment of melanoma tumors. Ga chelating agents can have high influence on physiological properties of Ga labeled bioactive molecules, as was experienced during the application of HBED-CC on PSMA ligand. The aim of this study was to assess this concept in the case of the melanin specific procaindamide (PCA) and to compare the melanin specificity of Ga-labeled PCA using HBED-CC and NODAGA chelators under in vitro and in vivo conditions. Procainamide (PCA) was conjugated with HBED-CC and NODAGA chelators and was labeled with Ga-68. The melanin specificity of Ga-HBED-CC-PCA and Ga-NODAGA-PCA was investigated in vitro and in vivo using amelanotic (MELUR and A375) and melanin containing (B16-F10) melanoma cell lines. Tumor-bearing mice were prepared by subcutaneous injection of B16-F10, MELUR and A375 melanoma cells into C57BL/6 and SCID mice. 21±2days after tumor cell inoculation and 90min after intravenous injection of the Ga-labelledlabeled radiopharmacons whole body PET/MRI scans were performed. Ga-NODAGA-PCA and Ga-HBED-CC-PCA were produced with excellent radiochemical purity (98%). In vitro experiments demonstrated that after 30 and 90min incubation time Ga-NODAGA-PCA uptake of B16-F10 cells was significantly (p≤0.01) higher than the Ga-HBED-CC-conjugated PCA accumulation in the same cell line. Furthermore, significant difference (p≤0.01 and 0.05) was found between the uptake of melanin negative and positive cell lines using Ga-NODAGA-PCA and Ga-HBED-CC-PCA. In vivo PET/MRI studies using tumor models revealed significantly (p≤0.01) higher Ga-NODAGA-PCA uptake (SUVmean: 0.46±0.05, SUVmax: 1.96±0.25,T/M ratio: 40.7±4.23) in B16-F10 tumors in contrast to Ga-HBED-CC-PCA where the SUVmean, SUVmax and T/M ratio were 0.13±0.01, 0.56±0.11 and 11.43±1.24, respectively. Melanin specific PCA conjugated with NODAGA chelator showed higher specific binding properties than conjugated with HBED-CC. The chemical properties of the bifunctional chelators used for Ga-labeling of PCA determine the biological behaviour of the probes. Due to the high specificity and sensitivity Ga-labeled PCA molecules are promising radiotracers in melanoma imaging.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
May 2017

[Clinical features of patients with juvenile and adult dermatomyositis].

Orv Hetil 2015 Sep;156(37):1491-6

Belgyógyászati Intézet, Klinikai Immunológiai Tanszék, Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Debrecen.

Introduction: Juvenile and adult dermatomysitis are chronic, immune-mediated inflammatory myopathies characterized by progressive proximal muscle weakness and typical skin symptoms.

Aim: To compare the symptoms, laboratory and serological findings, treatment and disease course in children and adults suffering from dermatomyositis.

Method: In this retrospective study, juvenile and adult dermatomyositis groups were formed. There were 27 patients with juvenile dermatomyositis (mean age, 8.7 years; mean follow-up time: 104.6 months) and 30 adult patients (mean age, 50.3; mean follow-up time: 58.1 months).

Results: In patients with juvenile dermatomyositis, treatment with intravenous immunoglobulin and cyclosporine A were more frequent as compared to adult patients. Acute onset of the disease was more frequent in adult patients than in those with juvenile disease. In children symptoms of the disease developed gradually.

Conclusions: The findings confirm previously published data showing that there are differences between juvenile and adult patients with dermatomyositis. The authors recommend to follow the patients regularly after reaching remission to avoid bad patient compliance and decrease the number and severity of relapses.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
September 2015